Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Last updated: November 4, 2024
Sponsor: Dana-Farber Cancer Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mucositis

Canker Sores

Treatment

THOR LX2.3 with LED Lollipop

Clinical Study ID

NCT05335434
22-036
  • Ages > 18
  • All Genders

Study Summary

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device.

The name of the study device involved in this study is:

  • THOR LX2.3 with LED Lollipop

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning andTac-Mtx GVHD prophylaxis.

  • Age ≥18 years.

  • Ability to understand and the willingness to sign a written informed consentdocument.

Exclusion

Exclusion Criteria:

  • Participants who have had treatment with intraoral PBMT within four weeks ofadmission for HSCT.

  • Participants who have a history of radiation therapy to the head and neck.

  • Participants who have a history of photosensitivity or underlying disease with knownphotosensitivity.

  • Participants who are planned to receive palifermin for OM prevention.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: THOR LX2.3 with LED Lollipop
Phase:
Study Start date:
June 10, 2022
Estimated Completion Date:
September 19, 2025

Study Description

As part of a transplant procedure patients will receive chemotherapy in a conditioning regimen in preparation of alloHCT as well as immunosuppressive medications to help prevent graft-versus-host disease ("GVHD prophylaxis"). Together, these treatments will put patients at risk for developing side effects. A common side effect is oral mucositis (OM), in which mouth sores develop making eating and speaking difficult and painful.

Photobiomodulation therapy (PBMT) is a light-based therapy that reduces inflammation and enhances wound healing. PBMT delivered inside the mouth has been shown to reduce OM in patients undergoing alloHCT.

The name of the study device involved in this study is:

  • THOR LX2.3 with LED Lollipop

This research study is a Pilot Study, which is the first time that investigators are examining this LED based intraoral PBMT.

The U.S. Food and Drug Administration (FDA) has not approved PBMT for this specific disease but it has been approved for other uses.

The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations.

Participants will receive study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first.

It is expected that about 20 people will take part in this research study

Connect with a study center

  • Brigham and Women's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.